Eric Lefkofsky To Help UChicago To Battle Breast Cancer
Eric Lefkofsky is the CEO as well as co-founder of Tempus. This is company dealing with technology. It has built an operating system that can help in the fight against cancer. Eric Lefkofsky is a founding partner of Lightbank which is a venture fund that invests in disruptive technologies.Eric Lefkofsky is the co-founder of Groupon and its Chairman too. This is a global e-commerce platform. He is the founder of Uptake Technologies which is an analytics platform for some of the largest industries in the world. He is also behind Mediaocean which provides various integrated procurement technologies. Echo Global Logistics is another transportation as well as logistics outsourcing company driven by technology that is promoted by Eric Lefkofsky. Next is InnerWorkings that is a provider of a number of print as well as promotional solutions globally.
Tempus is a cancer fighting startup. It comes from Eric Lefkofsky, the Groupon founder. With Tempus, Eric Lefkofsky wants to give data to doctors at the University of Chicago so that they can treat breast cancer patients in a much better way.Chicago-based Tempus has just announced its partnership with the University of Chicago Medicine Thursday. As per this partnership, Tempus will be providing molecular sequencing and analysis. This will be provided to the UChicago’s breast cancer specialists. It will help the doctors to create highly personalized treatment plans for their breast cancer patients. Here data will be analyzed from nearly 1,000 breast cancer patients. This type of data analysis will help doctors as well as researchers to uncover patterns that will be able to predict the response of patients to treatment.
Over time, it is expected that this data will help in providing better treatment along with highly improved patient outcomes.The fact is that breast cancer is one of the most common cancers today. But still there is very little accessible data that is available on the millions of patients who are battling or have battled this disease. Hence too many physicians are being forced to make treatment decisions with no help coming in from highly specific genetic information. Tempus will help them to make better informed decisions.